Quintrio
Home

SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE

LifeMD, Inc. Common Stock

LFMD

LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.

Last trade $1.80
Day change -$0.05 (-2.70%)
Day range $1.73 – $1.86
Volume 734,605
Market cap $89M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$89.42M
Price / earnings
—
Price / book
-154.26×
Price / sales
0.6×
EV / sales
0.45×
EV / EBITDA
-2.51×

Profitability

Earnings per share
-$0.07
Return on assets
-5.38%
Return on equity
615.68%
Dividend yield
3.47%

Liquidity and leverage

Debt / equity
-0×
Current ratio
0.8×
Quick ratio
0.63×
Cash ratio
0.36×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.21M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LFMD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$44.63M$47.28M$50.16M$7.08M$47.73M$49.02M$50.89M$5.49M
Cost of revenue$8.25M$5.28M$5.93M$4.23M$7.06M$6.84M$8.14M$6.8M
Gross profit$36.38M$42M$44.24M$2.85M$40.67M$42.18M$42.75M-$1.32M
Selling, general and administrative$35.51M$44.29M$45.05M$5.01M$39.15M$39.82M$36.61M-$274.47K
Research and development$1.88M$1.79M$1.8M-$920.05K$1.84M$1.82M$1.86M-$244.65K
Total operating expenses$40.84M$49.13M$53.17M$9.07M$43.79M$44.53M$43.93M$4.65M
Operating income-$4.47M-$7.13M-$8.93M-$6.22M-$3.13M-$2.35M-$1.18M-$5.97M
Interest expense-$3.21K$45.66K$56.48K$190.79K-$260.62K-$660.79K-$463.64K-$607.66K
Income before taxes-$4.47M-$7.08M-$8.87M-$6.03M-$4.54M-$3.01M-$1.65M-$6.58M
Income taxes$0$0$0-$123.41K$31.82K$0$0$365.48K
Net income-$4.47M-$7.08M-$8.87M$19.94M-$3.64M-$1.11M$348.07K-$4.63M
Net income attributable to common shareholders-$5.25M-$7.86M-$9.65M$19.19M-$4.67M-$2.4M-$960.34K-$5.72M
EBITDA-$7.52M-$5.09M-$6.93M-$7.39M-$5.96M-$561.54K$509.69K-$6.72M
Basic earnings per share-$0.11-$0.16-$0.20$0.41-$0.10-$0.05-$0.02-$0.14
Diluted earnings per share-$0.11-$0.16-$0.20$0.41-$0.10-$0.05-$0.02-$0.14

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

LifeMD: 3 Key Takeaways for Long-Term Investors

LifeMD announced strategic shifts including direct pharmacy partnerships with Eli Lilly and Novo Nordisk for GLP-1 medications, a major enterprise collaboration with AT&T providing access to 100 million customers, and lower introductory pricing that increased multi-month subscriptions from 25% to 85%. The company expects flat overhead while patient volume grows, positioning it well in the virtual care and pharmacy market.

Zacks Investment Research

LifeMD, Inc. (LFMD) Reports Q3 Loss, Misses Revenue Estimates

LifeMD (LFMD) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.14 loss by 21.43%, but missed revenue expectations with $44.63 million versus the estimated $48.81 million. The company's stock has declined 47.8% year-to-date compared to the S&P 500's 11.3% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market.

Zacks Investment Research

Omada Health, Inc. (OMDA) Q3 Earnings and Revenues Beat Estimates

Omada Health (OMDA) reported Q3 2026 earnings of $0.17 per share, beating consensus estimates of $0.09 by 88.89%, with revenues of $91.31 million exceeding expectations by 6.48%. The company has outperformed market estimates four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Peer company LifeMD is expected to report a quarterly loss of $0.14 per share with declining revenues.

Zacks Investment Research

Acadia Healthcare (ACHC) Surpasses Q3 Earnings and Revenue Estimates

Acadia Healthcare reported Q3 2026 earnings of $0.60 per share, beating consensus estimates of $0.46, with revenues of $895.31 million exceeding expectations by 3%. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions. The Medical-Hospital industry ranks in the bottom 7% of Zacks industries, which could limit future stock performance despite the company's strong year-to-date gains of 108.7%.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.